immunotherapy

The hybrid retreat showcased the latest gastric cancer, blood cancer, pediatric sarcoma, glioblastoma, breast cancer, and immune micro-environment research.

DCI researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire.

Congratulations to David Kirsch, MD, PhD, whose NCI Outstanding Investigator Award to study radiation and sarcoma biology has been renewed for another 7 years.

Brent Hanks, MD, PhD, and his lab team will trial a drug that targets the NLRP3 pathway, so as to unblock immunotherapy from working in melanoma patients.

The color blue and butterflies always make Jamie Cooper Moales think of her late sister, Sara Elizabeth Cooper.

Co-leader of the DCI Melanoma Disease Group Georgia Beasley, MD, MHSc, is among 40 recipients of a Young Physician-Scientist Award from The American Society for Clinical Investigation.

Elizabeth R. Hughes, PhD, an MGM postdoc, studies how gut microbes improve response to immune checkpoint inhibitors. She's been named a 2022 Robert Black Fellow by the Damon Runyon Cancer Research Foundation.

Zhao Zhang, PhD — ZZ to just about everyone — is a bit of a scientific outlier.

The Eighth Annual DCI Scientific Retreat was one for the books.

The $50,000 grant will support research by Chuan-Yuan Li, DSc, into the ability of cholesterol-lowering drugs to boost cancer-drug immunotherapies.

“I was feeling hopeless and as I was being treated by Dr. Crawford and Susan Blackwell, I started feeling hopeful of a future. I wanted to show this gratitude.”

A DCI-led research team has identified how melanoma tumors use estrogen signaling to trick the immune system into leaving them alone.

The V Foundation's Victory Ride to Cure Cancer was back as a LIVE cycling event and celebration, Aug. 28. Team DCI "virtual" and in-person riders raised more than $20K.

The $1.25 million grant from the Cancer Research Institute will support brain tumor immunotherapy research

Brent Hanks, MD, PhD, received the Conquer Cancer- Bristol-Myers Squibb Advanced Clinical Research Award in Immune Checkpoint Therapy.

DCI members Afreen Idris Shariff, MD, & Tian Zhang, MD, have launched a podcast on immune-related toxicities.

Can focusing on the immune system eradicate breast cancer?

A breast cancer researcher's study of estrogen action may lead to better treatments for other cancers.

A decade since it’s discovery in the Patz Lab, a first-in-class, novel targeted immunotherapy developed at DCI, is now in a phase 1b clinical trial.

Brent Hanks, MD, PhD, was named associate director of Translational Science for the Melanoma Disease Group this month.

An injectable drug used to reduce stubbornly high cholesterol levels appears in animal studies to also enhance the immune response of immune checkpoint inhibitors.

Diagnosed with stage 4 ovarian cancer three years ago, Kathy Jennings was thrown a lifeline when she came to Duke Cancer Center.

NCCN released new Guidelines for Patients in it's Immunotherapy Side Effects series, with the publication of a book focused on CAR T-Cell therapy.

NCCN announced the publication of new Guidelines for Patients in the Immunotherapy Side Effects series with the publication of a book on Immune Checkpoint Inhibitors.

The Duke Cancer Institute Virtual Grand Rounds Series, came to a successful summer close with its final session on June 19.

The research team found a signaling pathway within melanoma and other cancers that thwart the functioning of anti-PD-1 checkpoint inhibitors.

Suzanne L. Topalian, MD, Sidney Kimmel Comprehensive Cancer Center, delivers the Thomas J. Matthews Endowed Lecture, March 11 via livestream.

Using a precursor to dendritic cells appears to be an efficient and effective way to stimulate the immune system to fight cancer tumors, according to a study in animal and cell models.

Good news about Duke Cancer Institute's continued recognition as a leader in cancer research and care, and new investments in immunotherapy.

Translating Findings from a lab into patients in a clinic can be a long slog up a steep hill. The new DCI Center for Cancer Immunotherapy helps researchers with the climb.

Stephen Totty though he had simply pulled a pectoral muscle while moving furniture. But the soreness lingered. Then a painful “water balloon” full of blood developed.

Can research make immunotherapies work better, for more people?

Women with gynecological cancer have more treatment options than ever. Currently, Duke has 15 clinical trials open for women with gynecologic cancers.